SYNTAX II score was developed, 7 with the aim of improving clinical risk stratification, and facilitate the decision as to which revascularization technique should be preferred. The SS II besides the anatomical variables, includes also those clinical factors known to affect prognosis, such as unprotected left main disease, female gender, chronic obstructive pulmonary disease, left ventricular ejection fraction, renal function, and peripheral arterial disease (Figure 1) .
The study demonstrated that clinical outcomes with the SYNTAX II strategy were associated with improved clinical results compared with the PCI performed in similar patients from the original SYNTAX I trial, with a lower incidence of Major Adverse Cardiovascular Event (MACCE), as determined by a reduction of the individual endpoints: myocardial infarction, need for revascularization, stent thrombosis after 1 year of follow-up. 8 The main results of this study can be summarized as:
• Clinical outcomes with the SYNTAX II strategy were associated with improved clinical results compared with the PCI performed in similar patients from the original SYNTAX I trial with a lower incidence of MACCE, as determined by a reduction of the individual endpoints: myocardial infarction, need for revascularization, stent thrombosis after 1 year of follow-up.
• Short-term results of patients at intermediate anatomical risk (SS I 23-32) treated with PCI according to the SS II, had similar results than patients at low anatomical risk (SS I 22).
• A physiologic evaluation was possible in 75% of the lesions, and contributed to delaying the treatment of 25% of the lesion studied.
• The systematic use of IVUS (IntraVascularUltraSound) guided stent implantation determined a further stent optimization (mostly post-dilatation) in 32.2% of the lesion treated.
• Contemporary chronic total occlusion revascularization techniques are associated with significantly improved results.
The SYNTAX II study is the demonstration that PCI practiced with the improved technologic and pharmacologic strategies available today provides a better prognosis than the procedure employed for the patients in the SYNTAX I study. Furthermore, the decision to proceed with CABG should not only be based on the coronary anatomy (SS I 22), but should include the clinical parameters included in the SYNTAX II score. Second generation stents, IVUS guidance, iFR/FFR, and a careful implantation technique, all contributed to the improvement of the clinical results of PCI. The long-term follow-up of the study will provide information regarding the persistence of the results in the long term, and whether it is safe to delay treatment of coronary lesions based on iFR/FFR assessment.
In patients with 3VD, the choice between PCI or CABG should be made after careful assessment of the risks and benefits according to an overall evaluation which includes the anatomical/functional coronary situation and the clinical characteristics of every single patient. The choice, in light of the current data, is becoming more straightforward.
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